Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, because that oh-so-predictable routine of Zoom meetings, Skype calls and deadlines has returned. After all, the world keeps spinning. With that in mind, why not brew a cup of stimulation and give it a push? Our choice today is the ever-delicious maple bourbon. A fine way to start the day. Meanwhile, here are some tidbits to help you along. Hope your day is productive and do stay safe — wear a mask …

Merck (MRK) reported that an experimental Covid-19 drug, which promises to be a kind of Tamiflu for the pandemic, had positive results in a preliminary study, The Wall Street Journal says. The pill, which is being developed by Ridgeback Therapeutics, significantly reduced infectious virus in subjects in a mid-stage study after five days of treatment. If further study proves it capable of treating people with Covid-19 who show symptoms, the drug would bolster a limited arsenal of treatments and be the first oral antiviral against the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.